国药现代富马酸喹硫平缓释片获得药品注册证书

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern indicates the approval of the drug Fumaric Acid Quetiapine Extended-Release Tablets by the National Medical Products Administration, highlighting a significant development in the treatment of mental health disorders [1] Group 1: Company Information - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has received the drug registration certificate for Fumaric Acid Quetiapine Extended-Release Tablets [1] - The drug is classified as an atypical antipsychotic, aimed at regulating brain nerve activity and primarily used for managing schizophrenia and bipolar disorder [1] Group 2: Industry Implications - Fumaric Acid Quetiapine Extended-Release Tablets are designed to stabilize mood, reduce hallucinations, and improve cognitive confusion, thereby assisting patients in regaining normal cognitive and social functions [1]